Why the study?
Is tissue-type plasminogen activator (t-PA) worth the added expense compared to streptokinase in the treatment of acute myocardial infarction (AMI)?
Is tissue-type plasminogen activator (t-PA) worth the added expense compared to streptokinase in the treatment of acute myocardial infarction (AMI)?
Answers are grounded in this paper and cite their sources.
This article provides a clinical scenario to guide the critical appraisal of literature regarding the cost-effectiveness and clinical utility of t-PA versus streptokinase for AMI.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Michael Drummond (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: